<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyze the survival rate in 17 pediatric patients (twelve males and five females) that were diagnoses of non-Hodgkin's lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (cases with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were excluded) during the period from 1982 to 1990 </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of them were treated using the LSA2-L2 therapeutic protocol </plain></SENT>
<SENT sid="2" pm="."><plain>The follow-up period ranged from 14 to 99 months (follow-up median 43 months) </plain></SENT>
<SENT sid="3" pm="."><plain>Staging of our newly diagnosed patients, we found 9 patients in stage III and 8 in stage IV disease </plain></SENT>
<SENT sid="4" pm="."><plain>Survival was analyzed by the Kaplan-Meier method </plain></SENT>
<SENT sid="5" pm="."><plain>The overall survival rate of our patients is 69.5% and the disease free survival is 62.6% </plain></SENT>
<SENT sid="6" pm="."><plain>The disease free survival for separated stages is 66.5% for stage III and 58.3% for stage IV </plain></SENT>
<SENT sid="7" pm="."><plain>We compare our results with other casuisties published in literature </plain></SENT>
</text></document>